Oral, Injectable, and Infusion Multiple Sclerosis Treatments: Key Differences

Understanding Disease‑Modifying Therapies (DMTs)

Multiple sclerosis (MS) is an autoimmune disease with no cure, but disease‑modifying therapies (DMTs) can slow progression, reduce relapses, and limit new damage. The U.S. Food and Drug Administration (FDA) regulates all DMTs and issues safety warnings for drugs with higher risk profiles.

How DMTs Are Delivered

DMTs reach the body in three main ways:

• Oral: tablets, capsules, or liquids taken at home.
• Injectable (non‑oral): administered subcutaneously, intramuscularly, or via a port‑a‑catheter. Many are self‑injected; some require a nurse or clinic visit.
• Infusion: intravenous (IV) medications given in a clinic or hospital by a healthcare professional.

Oral Medications

Oral DMTs are the easiest to self‑administer and usually require daily or twice‑daily dosing. Below is a list of FDA‑approved oral agents.

Aubagio (teriflunomide)

• Benefit: Immune‑modulator that also inhibits nerve degeneration.
• Dosing: One tablet daily.
• Common side effects: Headache, liver enzyme elevation, nausea, hair loss, reduced white‑blood‑cell (WBC) count.
• Warnings: Risk of severe liver injury and birth defects; requires regular liver monitoring.

Bafiertam (monomethyl fumarate)

• Benefit: Reduces inflammatory immune response; may protect brain and spinal cord.
• Dosing: 95 mg capsule twice daily for 7 days, then two capsules daily.
• Common side effects: Allergic reactions, gastrointestinal upset, increased infection risk.
• Warnings: Not for patients with low WBC counts.

Gilenya (fingolimod)

• Benefit: Prevents T‑cells from leaving lymph nodes.
• Dosing: One tablet daily.
• Common side effects: Flu‑like symptoms, elevated liver enzymes.
• Warnings: May affect blood pressure, heart rhythm, and liver function.

Mavenclad (cladribine)

• Benefit: Reduces T‑ and B‑cell numbers without continuous immune suppression.
• Dosing: Two short treatment courses separated by ~1 year; each course consists of 2 doses 23‑27 days apart.
• Common side effects: Upper‑respiratory infections, headache, lymphopenia.
• Warnings: Increased cancer risk; contraindicated in pregnancy.

Ponesimod (Ponvory)

• Benefit: Retains certain white‑blood cells in lymph nodes, limiting CNS entry.
• Dosing: 20 mg tablet once daily.
• Common side effects: Upper‑respiratory infections, liver issues, high blood pressure.
• Warnings: Not for patients with cardiac history.

Siponimod (Mayzent)

• Benefit: Modulates immune cells to slow progression and reduce relapses.
• Dosing: 2 mg tablet once daily.
• Common side effects: Bradycardia, headache, hypertension, eye problems, infections, lung issues, liver injury.
• Warnings: Contra‑indicated in cardiac disease, stroke, and pregnancy.

Tecfidera (dimethyl fumarate)

• Benefit: Anti‑inflammatory; protects nerves and myelin.
• Dosing: Two capsules daily.
• Common side effects: GI upset, reduced WBC count, elevated liver enzymes.
• Warnings: Can cause severe allergic reactions, including anaphylaxis.

Vumerity (diroximel fumarate)

• Benefit: Likely modulates immune response to reduce inflammation.
• Dosing: One capsule daily for 7 days, then two capsules with a high‑fat meal.
• Common side effects: Flushing, skin irritation, nausea, GI upset.
• Warnings: Possible allergic or infection risk.

Zeposia (ozanimod)

• Benefit: Prevents certain WBCs from entering the CNS.
• Dosing: One capsule daily.
• Common side effects: Liver enzyme changes, hypertension, bradycardia, respiratory infections.
• Warnings: Not suitable for patients with cardiac disease or stroke.

Injectable (Non‑Oral) DMTs

Injectable DMTs are given subcutaneously, intramuscularly, or through a port‑a‑catheter. Some are self‑administered; others require a nurse or clinic visit.

Avonex (interferon beta‑1a)

• Benefit: Immune‑modulator.
• Dosing: 30 µg intramuscular injection once weekly.
• Common side effects: Headache, flu‑like symptoms.
• Warnings: Monitor liver enzymes and CBC.

Betaseron (interferon beta‑1b)

• Benefit: Immune‑modulator.
• Dosing: 0.25 mg subcutaneous injection every other day.
• Common side effects: Flu‑like symptoms, low WBC count.
• Warnings: Monitor liver enzymes and CBC.

Copaxone (glatiramer acetate)

• Benefit: Immune‑modulator; blocks myelin attack.
• Dosing: 20 mg daily or 40 mg three times weekly subcutaneously.
• Common side effects: Flushing, shortness of breath, rash, chest pain.
• Warnings: Possible permanent skin indentation; rotate injection sites.

Extavia (interferon beta‑1b)

• Benefit: Immune‑modulator.
• Dosing: 0.25 mg subcutaneous injection every other day.
• Common side effects: Flu‑like symptoms, headache.
• Warnings: Monitor liver enzymes and CBC.

Glatopa (glatiramer acetate)

• Benefit: Immune‑modulator; blocks myelin attack.
• Dosing: 20 mg daily or 40 mg three times weekly subcutaneously.
• Common side effects: Redness, swelling, pain at injection site.
• Warnings: Possible skin indentation; rotate sites.

Kesimpta (ofatumumab)

• Benefit: Depletes B‑cells that cause nerve damage.
• Dosing: Weekly subcutaneous injections for 4 weeks, then monthly.
• Common side effects: Injection‑site reactions, fever, flu‑like symptoms, URIs, headache.
• Warnings: Discuss dosing adjustments for hepatitis B infection or vaccination with your doctor.

Plegridy (pegylated interferon beta‑1a)

• Benefit: Immune‑modulator.
• Dosing: 125 µg subcutaneous injection every 2 weeks.
• Common side effects: Flu‑like symptoms.
• Warnings: Monitor liver enzymes.

Rebif (interferon beta‑1a)

• Benefit: Immune‑modulator.
• Dosing: 22 µg subcutaneous injection three times weekly.
• Common side effects: Flu‑like symptoms.
• Warnings: Monitor liver enzymes.

Infusion (IV) Therapies

Infusion DMTs are administered intravenously in a clinic or hospital by a trained professional. Dosing intervals are generally longer than for injectables.

Lemtrada (alemtuzumab)

• Benefit: Suppresses myelin‑damaging immune cells.
• Dosing: 5 days of daily infusions, then 3 days a year later.
• Common side effects: Nausea, vomiting, diarrhea, headache, rash, itching.
• Warnings: Risk of cancer and immune thrombocytopenic purpura (ITP).

Mitoxantrone (Novantrone)

• Benefit: Immune‑modulator and suppressor.
• Dosing: 1 infusion every 3 months; lifetime limit of 8‑12 infusions.
• Common side effects: Hair loss, nausea, amenorrhea.
• Warnings: Potential heart damage and leukemia; reserved for severe RRMS.

Ocrevus (ocrelizumab)

• Benefit: Targets B‑cells that damage nerves.
• Dosing: Two 300 mg IV infusions 2 weeks apart, then every 6 months.
• Common side effects: Flu‑like symptoms, infections.
• Warnings: Possible malignancy and rare life‑threatening infusion reactions.

Tysabri (natalizumab)

• Benefit: Inhibits adhesion molecules, reducing immune cell migration.
• Dosing: 300 mg IV infusion every 4 weeks.
• Common side effects: Headache, joint pain, fatigue, depression, abdominal discomfort.
• Warnings: Increased risk of progressive multifocal leukoencephalopathy (PML), a potentially fatal brain infection.

Choosing the Right DMT

When selecting a therapy, consider the following factors:

• Effectiveness for your disease course.
• Side‑effect profile and monitoring requirements.
• Dosing frequency and convenience.
• Method of administration (oral, self‑injectable, clinic‑based).

The overarching goal of MS treatment is to manage symptoms, control relapses, and slow long‑term disease progression. Adherence to the prescribed regimen—whether oral, injectable, or infused—is essential for optimal outcomes.

If side effects or dosing schedules become challenging, discuss alternatives with your neurologist. They can help you find a therapy that fits your lifestyle and medical needs.